MX2012002597A - Nuevos inhibidores de la lipasa sensible a las hormonas (hsl) utiles para el tratamiento de la diabetes. - Google Patents
Nuevos inhibidores de la lipasa sensible a las hormonas (hsl) utiles para el tratamiento de la diabetes.Info
- Publication number
- MX2012002597A MX2012002597A MX2012002597A MX2012002597A MX2012002597A MX 2012002597 A MX2012002597 A MX 2012002597A MX 2012002597 A MX2012002597 A MX 2012002597A MX 2012002597 A MX2012002597 A MX 2012002597A MX 2012002597 A MX2012002597 A MX 2012002597A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- treatment
- diabetes
- esters
- salts
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 5
- 150000002148 esters Chemical class 0.000 abstract 4
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170071 | 2009-09-11 | ||
| PCT/EP2010/063078 WO2011029808A1 (en) | 2009-09-11 | 2010-09-07 | Hsl inhibitors useful in the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002597A true MX2012002597A (es) | 2012-04-02 |
Family
ID=42983383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002597A MX2012002597A (es) | 2009-09-11 | 2010-09-07 | Nuevos inhibidores de la lipasa sensible a las hormonas (hsl) utiles para el tratamiento de la diabetes. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8258158B2 (OSRAM) |
| EP (1) | EP2475644B1 (OSRAM) |
| JP (1) | JP5642793B2 (OSRAM) |
| KR (1) | KR101369551B1 (OSRAM) |
| CN (1) | CN102498099B (OSRAM) |
| AR (1) | AR078351A1 (OSRAM) |
| AU (1) | AU2010294326A1 (OSRAM) |
| BR (1) | BR112012005140A2 (OSRAM) |
| CA (1) | CA2771452A1 (OSRAM) |
| ES (1) | ES2445166T3 (OSRAM) |
| IL (1) | IL217966A0 (OSRAM) |
| IN (1) | IN2012DN01232A (OSRAM) |
| MX (1) | MX2012002597A (OSRAM) |
| SG (1) | SG179031A1 (OSRAM) |
| TW (1) | TW201114744A (OSRAM) |
| WO (1) | WO2011029808A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012230503B2 (en) | 2011-03-18 | 2016-07-07 | Bayer Intellectual Property Gmbh | N-(3-carbamoylphenyl)-1H-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests |
| JP6263789B2 (ja) * | 2012-09-10 | 2018-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 |
| JP7007381B2 (ja) * | 2016-12-09 | 2022-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド |
| GB2560713A (en) * | 2017-03-20 | 2018-09-26 | Eternygen Gmbh | Inhibitor of citrate transporter |
| CN110003177B (zh) * | 2019-05-28 | 2021-11-19 | 沈阳药科大学 | 含有脲基的苯并咪唑类化合物及应用 |
| CN110003176B (zh) * | 2019-05-28 | 2021-12-21 | 沈阳药科大学 | 含有酰胺的苯并咪唑类化合物及其应用 |
| GB201918410D0 (en) | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
| WO2022130352A1 (en) * | 2020-12-19 | 2022-06-23 | Cadila Healthcare Limited | Novel compounds suitable for the treatment of dyslipidemia |
| GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3779339B2 (ja) | 1994-03-04 | 2006-05-24 | 三井化学株式会社 | 含フッ素カルボン酸エステル化合物、液晶材料、液晶組成物および液晶素子 |
| WO1999065867A1 (en) * | 1998-06-17 | 1999-12-23 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| JP2005509032A (ja) | 2001-11-14 | 2005-04-07 | シェーリング コーポレイション | カンナビノイドレセプターリガンド |
| CN101133026B (zh) * | 2005-03-03 | 2011-07-06 | 霍夫曼-拉罗奇有限公司 | 作为治疗Ⅱ型糖尿病用的11β-羟基类固醇脱氢酶抑制剂的1-磺酰基-哌啶-3-羧酸酰胺衍生物 |
| AR059246A1 (es) * | 2006-01-30 | 2008-03-19 | Array Biopharma Inc | Compuestos heterobiciclicos de tiofeno y metodos de uso |
| JP2009539937A (ja) * | 2006-06-16 | 2009-11-19 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 置換型ピペリジンカルボキサミドの医薬的使用 |
| EP1958631A1 (en) | 2007-02-14 | 2008-08-20 | AEterna Zentaris GmbH | Novel triazole derivatives as ligands of G-protein coupled receptors |
| US8324250B2 (en) | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8399676B2 (en) * | 2009-07-30 | 2013-03-19 | Hoffman-La Roche Inc. | Piperidine derivatives |
-
2010
- 2010-09-03 US US12/875,446 patent/US8258158B2/en not_active Expired - Fee Related
- 2010-09-07 IN IN1232DEN2012 patent/IN2012DN01232A/en unknown
- 2010-09-07 MX MX2012002597A patent/MX2012002597A/es active IP Right Grant
- 2010-09-07 WO PCT/EP2010/063078 patent/WO2011029808A1/en not_active Ceased
- 2010-09-07 SG SG2012016085A patent/SG179031A1/en unknown
- 2010-09-07 EP EP10751931.6A patent/EP2475644B1/en not_active Not-in-force
- 2010-09-07 CA CA2771452A patent/CA2771452A1/en not_active Abandoned
- 2010-09-07 AU AU2010294326A patent/AU2010294326A1/en not_active Abandoned
- 2010-09-07 KR KR1020127009254A patent/KR101369551B1/ko not_active Expired - Fee Related
- 2010-09-07 CN CN201080039803.8A patent/CN102498099B/zh not_active Expired - Fee Related
- 2010-09-07 ES ES10751931.6T patent/ES2445166T3/es active Active
- 2010-09-07 JP JP2012528339A patent/JP5642793B2/ja not_active Expired - Fee Related
- 2010-09-07 BR BR112012005140A patent/BR112012005140A2/pt not_active Application Discontinuation
- 2010-09-08 TW TW099130350A patent/TW201114744A/zh unknown
- 2010-09-09 AR ARP100103302A patent/AR078351A1/es unknown
-
2012
- 2012-02-06 IL IL217966A patent/IL217966A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5642793B2 (ja) | 2014-12-17 |
| JP2013504533A (ja) | 2013-02-07 |
| EP2475644A1 (en) | 2012-07-18 |
| US20110065707A1 (en) | 2011-03-17 |
| IN2012DN01232A (OSRAM) | 2015-05-15 |
| KR20120059617A (ko) | 2012-06-08 |
| HK1169993A1 (en) | 2013-02-15 |
| TW201114744A (en) | 2011-05-01 |
| WO2011029808A1 (en) | 2011-03-17 |
| AR078351A1 (es) | 2011-11-02 |
| US8258158B2 (en) | 2012-09-04 |
| CN102498099A (zh) | 2012-06-13 |
| KR101369551B1 (ko) | 2014-03-04 |
| AU2010294326A1 (en) | 2012-03-08 |
| EP2475644B1 (en) | 2014-01-08 |
| SG179031A1 (en) | 2012-04-27 |
| CN102498099B (zh) | 2014-10-29 |
| BR112012005140A2 (pt) | 2016-05-03 |
| IL217966A0 (en) | 2012-03-29 |
| CA2771452A1 (en) | 2011-03-17 |
| ES2445166T3 (es) | 2014-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG179031A1 (en) | Hsl inhibitors useful in the treatment of diabetes | |
| MX2011012017A (es) | Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). | |
| TN2012000125A1 (en) | Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors | |
| GEP20125487B (en) | Organic compounds and their use | |
| TW200740789A (en) | Pyridine and pyrimidine derivatives as mGluR2 antagonists | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| TW200716121A (en) | Acetylenyl-pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| MX2008014101A (es) | Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos. | |
| NZ601121A (en) | 5-alkynyl-pyrimidines | |
| MX2011007192A (es) | Composicion farmaceutica. | |
| MY149731A (en) | Compounds | |
| MX2010009922A (es) | Activadores de piridazinona glucocinasa. | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| IL192847A (en) | The history of benzamide and the trower, a process for making them and their pharmaceutical preparations | |
| TW200806300A (en) | New therapeutic combinations for the treatment of depression | |
| MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| MX2013004759A (es) | Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl). | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| MX383551B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida | |
| WO2011047055A8 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |